Clinical Efficacy of Yiqi Yangrong Prescription for Myelosuppression after Chemo-therapy in Patients with Non-small Cell Lung Cancer
Objective To explore the clinical efficacy of Yiqi Yangrong Prescription in treating myelosuppression in patients with non-small cell lung cancer(NSCLC)after chemotherapy.Methods A total of 120 NSCLC patients with chemotherapy-induced myelosuppression,treated at the Traditional Chinese Medicine Rehabilitation Department of Cang-zhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine from June 2018 to June 2020,were select-ed and randomly divided into a control group and an experimental group according to a random number table,with 60 pa-tients in each group.The control group was treated with meropenem,while the experimental group received Yiqi Yangrong Prescription in addition to meropenem.Both groups were treated for 2 weeks.The myelosuppression,incidence of adverse reactions,peripheral blood cell count,traditional Chinese medicine(TCM)symptom scores,and quality of life scores were compared between the two groups before and after treatment.Results After treatment,white blood cell,granulocyte,and platelet levels decreased,while hemoglobin levels increased significantly in both groups compared to those before treatment(P＜0.05).The peripheral blood cell counts in the experimental group were significantly better than those in the control group(P＜0.05).TCM symptom scores for cough with little sputum,weak cough,fatigue,tidal fever and night sweats,diz-ziness,and pale complexion were significantly lower in both groups after treatment(P＜0.05),with the experimental group showing significantly lower scores than the control group(P＜0.05).Quality of life scores for emotional,social,physical,role,and cognitive functions,as well as overall health,significantly increased in both groups after treatment(P＜0.05),with the experimental group scoring significantly higher than the control group(P＜0.05).The myelosuppression grades of 0,Ⅱ,Ⅲ,and Ⅳ in the experimental group were significantly lower than those in the control group(P＜0.05),although there was no significant difference in grade 0 between the two groups(P＞0.05).During treatment,the incidence of ad-verse reactions was not significantly different between the two groups(P＞0.05).Conclusion Compared to treatment with meropenem alone,the combined use of meropenem and Yiqi Yangrong Prescription results in better improvement of myelo-suppression in NSCLC patients after chemotherapy.This combination therapy shows better efficacy in myelosuppression and fewer adverse reactions,indicating higher safety.
Small Cell Lung CancerChemotherapyMyelosuppressionYiqi Yangrong Prescription
NETL
NSTL
万方数据
